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Abstract
Background: Intestinal cell kinase (ICK; GeneID 22858) is a conserved MAPK and CDK-like kinase that is widely 
expressed in human tissues. Data from the Cancer Genome Anatomy Project indicated ICK mRNA is increased in 
cancer, and that its expression correlated with expression of mRNA for an uncharacterized F-box protein, FBX9 (GeneID: 
26268). ICK and FBX9 genes are arranged head-to-head on opposite strands, with start sites for transcription separated 
by ~3.3 kb. We hypothesized ICK and FBX9 are potentially important genes in cancer controlled by a bidirectional 
promoter.
Results: We assessed promoter activity of the intergenic region in both orientations in cancer cell lines derived from 
breast (AU565, SKBR3), colon (HCT-15, KM12), and stomach (AGS) cancers, as well as in embryonic human kidney 
(HEK293T) cells. The intergenic segment was active in both orientations in all of these lines, and ICK promoter activity 
was greater than FBX9 promoter activity. Results from deletions and truncations defined a minimal promoter for ICK, 
and revealed that repressors and enhancers differentially regulate ICK versus FBX9 promoter activity. The ICK promoter 
contains consensus motifs for several FOX-family transcription factors that align when mouse and human are 
compared using EMBOSS. FOXA1 and FOXA2 increase luciferase activity of a minimal promoter 10-20 fold in HEK293T 
cells. Consensus sites for TCF7L2 (TCF4) (Gene Id: 6934) are also present in both mouse and human. The expression of 
β-catenin increased activity of the minimal promoter ~10 fold. ICK reference mRNAs (NM_014920.3, NM_016513) are 
expressed in low copy number and increased in some breast cancers, using a ten base tag 5'-TCAACCTTAT-3' specific 
for both ICK transcripts.
Conclusion: ICK and FBX9 are divergently transcribed from a bidirectional promoter that is GC-rich and contains a CpG 
island. A minimal promoter for ICK contains functional sites for β-cateinin/TCF7L2 and FOXA. These data are consistent 
with functions that have been proposed for ICK in development and in proliferation or survival of some breast and 
colon cancers.
Background
The ICK gene encodes an evolutionarily conserved Ser/
Thr kinase in the CMGC group of the kinome, clustering
in a subgroup with closely related MAK (male germ cell-
associated protein kinase) and more distantly related
MOK (MAPK/MAK/MRK overlapping kinase) [1]. ICK
was first identified and named MRK (MAK-related pro-
tein kinase) after cloning of its cDNA from heart [2]).
ICK expression was higher in the embryonic myocardium
during organogenesis than in the adult tissue [2].
Decreasing expression of ICK in Colo205 cells stops pro-
liferation and causes cell cycle arrest in G1 due to an
increase in p21Cip [3]. Colo205 cells greatly overexpress
ICK mRNA in comparison to other lines in the NCI60,
suggesting an acquired addiction to ICK for proliferation
in this line. ICK mRNA is detectable in normal intestinal
epithelium only in the region for lineage specification and
proliferation [4].
ICK has to be phosphorylated in a TDY motif (residues
157-159) within the activation loop to be fully active.
Phosphorylation of Y159 can occur by autophosphoryla-
tion, but at least phosphorylation of T157 requires trans-
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phosphorylation by another kinase [1]. ICK is a substrate
for a T157-kinase related to CDK-activating kinase with
gene name CCRK (cell cycle regulated kinase, [GenBank:
NM_001039803]). CCRK (NM_001039803) unequivo-
cally has T157 kinase activity because wild type but not a
kinase-defective mutant phosphorylates T157 in cells [1].
Decreasing CCRK expression ~80% markedly inhibited
proliferation of HCT116 and U2OS cells without a signif-
icant, specific change in G1, M, or G2/M populations but
modestly increased the population with sub-G1 DNA
content, suggesting increased apoptosis [5]. Other
reports support a role for CCRK in molecular carcino-
genesis of ovarian cancer [6]. CCRK-specific gene silenc-
i n g  c a u s e s  o v a r i a n  c a n c e r  c e l l s  t o  a r r e s t  i n  G 1  [ 6 ] .
Recently, CCRK was identified as an interactor of Broad-
minded in Sonic hedgehog pathways [7].
Results
FBX9 and ICK expression are correlated genes
The NCI60 is a panel of cancer cell lines for the Cancer
Genome Anatomy Project (CGAP). FBX9 expression cor-
relates (R = 0.45, P = 1.5 e-04) with ICK expression in the
NCI60 amongst genes present in microarrays from a very
large collection of cDNAs. We took note because FBX9 is
the neighboring gene to ICK. FBX9 encodes an uncharac-
terized F-box protein [8]. The two genes are on opposite
strands, arranged head-to-head with their predicted start
sites separated by only ~3.3 kb. These data suggested the
intergenic segment might have bidirectional promoter
activity.
We also were interested in using the intergenic segment
to gain insights to ICK regulation that in turn might sug-
gest functions. Expression of ICK mRNA is confined to
the region in normal mouse epithelium where prolifera-
tion and lineage specifications occur and where β-
catenin/TCF7L2 (referred to herein as TCF4) is most
active. Loss of a tumor suppressor causes activation of β-
catenin/TCF4 in colon cancers [9]. We hypothesized that
ICK promoter activity may be increased in colon cancer
cell lines (KM12, HCT-15) and in stomach cancer cells
(AGS) because of this correlation. We also studied breast
cancer cell lines (AU565 and SK-BR3-3) because β-
catenin/TCF4 is highly active in breast cancers [10].
The FBX9-ICK intergenic segment has bidirectional 
promoter activity
We obtained a clone (RP3-341E18, [GenBank:
AL031178]) for a portion of the p12.3-p11.2 region of
human chromosome 6 from the Sanger Institute. One
XhoI restriction fragment contains the intergenic region
and the start sites for transcription of both genes. This 4.5
kilobase fragment and portions thereof were placed into
the promoterless pGL3-luciferase plasmid so as to gener-
ate constructs (pGL3-PICK: 1-12 and pGL3-PFBX9: 1-5),
shown schematically in (Fig. 1). We refer to constructs as
ICK-1 to 12 and as FBX9-1 to 5. We used these constructs
to study the promoter in five human cancer cell lines as
well as in HEK293T.
The full intergenic segment (constructs ICK-1 and
FBX9-1) was active in both orientations in all six of the
lines, suggesting that ICK and FBX9 share a bidirectional
promoter. Analyses in the different lines (Figs. 2, 3, 4)
show elements in the common SspIb to PstIb fragment are
important for bidirectional activity, and may account for
the correlated expression of FBX9 and ICK in microarray
data that motivated this study. Our analyses (Figs. 2, 3,
&4) show that the intergenic segment is not a constitu-
tive, bidirectional promoter because the FBX9 activity
relative to ICK activity is variable.
Promoter activity in HER2-overexpressing breast cancer 
cells
ICK promoter activity was 10-20 fold higher than FBX9
promoter activity in AU565 and SKBR3 cells, using con-
structs ICK-1 and FBX9-1 which contain the full inter-
genic segment (Fig. 2). Moreover, AU565 and SKBR3 gave
similar patterns of relative activity between the different
constructs derived from ICK-1 and FBX9-1. This may
relate to the fact that AU565 and SKBR3 were obtained
from pleural effusions from the same patient [11]. The
Figure 1 Restriction map of genomic DNA between FBX9 and ICK 
and pGL3 constructs. Indicated fragments were cloned into promot-
er-less pGL3 for luciferase (Luc) expression. Arrows, start of transcrip-
tion for reference ICK and FBX9 mRNAs.
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results obtained with the truncation constructs (ICK-2 to
7) reveal enhancer elements within the SspIb-EcoRVa seg-
ment and a suppressor element within the unique EcoRV-
EcoRV fragment. The internal deletions (ICK-10 to 12)
indicate another enhancer element for ICK lies in
EcoRVb-PstIb close to the ICK start site. Removal of this
segment reduces ICK promoter activity 40% in both
AU565 and SKBR3 cells. Extending the internal deletion
from Pst1b back to SspIb (ICK-11), or further back to SspIa
(ICK-12), had modest and opposite effects. The region
from SspIb to PstIb is particularly complex, and appears
likely to have several important elements. This conclu-
sion is borne out by data obtained from the other lines.
Promoter activity in colon cancer cells
KM12 and HCT-15 are two colon cancer cell lines. Both
are near diploid, and have relatively few structural rear-
rangements confined to 7 chromosomes [12]. The pat-
terns of luciferase activity created by the constructs in
these two cancer cell lines are quite different (Fig. 3).
KM12 has homozygous loss for a lysine (K)-specific dem-
ethylase 6A (KDM6A); a ubiquitously transcribed X
chromosome tetratricopeptide repeat protein; homozy-
gous loss of PTEN; and heterozygous loss of p53 func-
tions. (Some mutations in the NCI60 are available online
http://www.sanger.ac.uk/). HCT-15 is null for function of
APC, BRAC2, and FAM123 tumor suppressors, and has
homozygous loss of p53 along with oncogenic mutations
in KRAS, PI3KCα, and MSH6. The results for truncations
for ICK in KM12 suggest an enhancer in SspIb-EcoRVa,
and a suppressor in the unique EcoRV-EcoRV segment,
and provide strong evidence for an enhancer in EcoRVb -
PstIb. The internal deletions for ICK (ICK-10 to 12) also
strongly support this enhancer. Specific removal of
EcoRVb - PstIb with ICK-10 caused a large decrease in
activity, and this phenomenon was observed to different
degrees in all six lines. Extending the internal deletion to
SspIb (ICK-11) or to SspIa (ICK-12) resulted in modest
changes by comparison. The largest change in activity in
HCT-15 occurred with deletion of EcoRVb-PstIb.
Promoter activity in AGS gastric cancer and HEK293T 
kidney cells
AGS is a human gastric cancer line that robustly
expresses ICK mRNA [4]. HEK293T cells are human
embryonic fibroblasts that were originally immortalized
by transformation with sheared adenovirus [13], and
much later made to express the large T antigen of SV40.
AGS is similar to KM12 in pattern of luciferase activity
between constructs, and HEK293 is similar to HCT-15
(Fig. 4). Results from AGS, like KM12 discussed above,
Figure 2 FBX9 and ICK are divergently transcribed from a bidirec-
tional promoter. Equal numbers of SKBR3 and AU565 cells were seed-
ed into 96-well plates, transfected with the indicated constructs 
(Figure 1), then assayed for luciferase activity in each well by the meth-
ods described. Data in figures 2 and 3 were obtained by the same pro-
cedures. Bar, ± S.D.
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Figure 3 The SspIb to PstIb segment contains enhancer and sup-
pressor elements. Equal numbers of KM12 and HCT-15 colon cancer 
cells were seeded into 96-well plates, transfected with the indicated 
constructs (Figure 1), then assayed for luciferase activity in each well by 
the methods described. Bar, ± S.D.
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support regulatory elements within ApaIa-ApaIb, and
confirm the enhancer in SspIb-EcoRVa and the suppressor
in the unique EcoRV-EcoRV. Overall, both the trunca-
tions and the internal deletions in AGS and HEK293
strongly support importance of EcoRVb-PstIb.
Conserved FOX binding motifs in human and mouse ICK 
promoters
Promoters for ICK and FBX9 are similarly configured on
mouse Chr9 in a head-to-head fashion with starts for
transcription on opposite strands. Because prediction of
transcription factor sites is difficult at best and there are
many false positive, we looked for conserved motifs pres-
ent in both mouse and human that are well characterized
in literature.
A striking finding was a number of consensus motifs
for fork head box (FOX) proteins. Many FOX proteins
bind a conserved motif with a core of TGTTTR, where R
is (G, A) [14]. Also striking was the presence of a number
of aligned, conserved TG motifs (TTTGTT, TTT-
GTTTT, TTTTGTTTGTTTT). FOX is a large family of
sequence-specific factors. Its members regulate expres-
sion of many genes involved in cell growth, proliferation,
differentiation and development [15,16]. The first protein
in the FOX family was the Drosophila gene named fork
head. (Prior to year 2000, certain human FOX proteins
had several aliases, as winged helix protein proteins, as
hepatocyte nuclear factors (HNFs), or forkhead-related
clones (FREAC). For example, FOXA1 and 2 were HNF3α
and β.) The winged helix domain of FOXA (HNF3) binds
optimally to a consequence WWTRTTTRYWYD
sequence [17], where W is (A/T), R is (A/G), Y is (C/T),
and D is (A/C/T).
A motif, 5'-ATAGGTAAACA-3', near -1217 nt in
human ICK, is predicted to bind FOX proteins, possibly
FOXD1 and FOXJ2 (Fig. 5). This motif has a conserved
GTAAACA core known to bind FOXD1 (FREAC-4) and
FOXF2 (FREAC-2). Bases that differentiate between fam-
ily members lie near this core [14]. FOXJ2 functions in
gametogenesis and early embryonic development [18].
FOXD1 functions in development of the retina [19]. A
motif, 5'-GCCTTTTGTTTGTTTT-3' (near -30 nt in
human), is conserved between mouse and human and
contains a consensus match to FOX proteins expressed in
embryonic tissues, possibly FOXJ1 or FOXJ2 (Fig. 6). This
motif also matches the core for FOXA.
Beginning near PstIb (Fig. 6) is a region of near identity
that surrounds the transcription start sites for ICK. This
region is GC-rich, and has conserved CpG sites concen-
trated as a CpG island. This region [NCBI gi: 1038509]
was isolated in a genome-wide purification of un-methy-
lated CpG islands [20]. CpG islands overlap the 5'end of
genes, and often contain the promoter and one or more
exons of genes [20]. Methylations can differentially regu-
late recognition by transcription factors [21]. Methyla-
tions at CpG can also change gene expression in
development in set programs of activation and silencing
[22], and remain as a source of epigenomic variation [23].
The putative activator of ICK, CCRK, is transcribed from
a 5' start in a CpG island that is variably methylated in
adult brain tissues [23].
Minimal ICK promoter in HEK293T and HCT-15 cells
To enable initial studies of transcription factors, we chose
a minimal ICK promoter for use in HEK293T cells. Activ-
ity in HEK293T (Fig. 3) and HCT-15 (Fig. 4) cells did not
depend greatly on SspIa-SspIb  and SspIb-EcoRVa  frag-
ments. To compare data from these lines, we normalized
our promoter data for ICK constructs to ICK-9 (Fig. 7).
Activity of the full ICK promoter (ICK-1) is increased 13-
14 fold in both of these lines. The normalized results for
truncations from the 5' end show that elements required
for luciferase activity in HEK293T and HCT-15 cells
reside in the EcoRVa-EcoRVb (611 nt) fragment and the
EcoRVb-Pst1 (503 nt) fragment. ICK-6 and ICK-7 also
retain the majority of reporter activity for ICK in the
other cell lines. The first and second EcoRV cut sites are
Figure 4 The GC-rich EcoRVb-PstIb segment is required for ICK re-
porter activity. Equal numbers of AGS stomach cancer cells and 
HEK293T cells were seeded into 96-well plates, transfected with the in-
dicated constructs (Figure 1), then assayed for luciferase activity in 
each well by the methods described. Bar, ± S.D.
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1195 and 587 nt, respectively, from the predicted tran-
scription start site of human ICK. Two alternative refer-
ence mRNAs (NM_016513, NM_014920) use the same
start site GGAAAAC within PstIb-ApaIc. We chose the
smaller construct ICK-7 (~0.8 kb), with ~0.6 kb of 5'
sequence, as the minimal promoter to study in the next
experiments.
FOXA and β-catenin activate the ICK minimal promoter in 
HEK293T cells
We next asked if any transcription factors of importance
for intestinal crypts regulate the chosen minimal pro-
moter (ICK-7) in co-expression experiments in
HEK293T. Both FOXA1 and FOXA2 caused large
increases in luciferase activity (Fig. 8). FOXM1, which
regulates mitotic progression, had no effect in these
Figure 5 Alignment of the human and mouse ICK promoter sequence for the SspIa to EcoRVa fragment. Line numbers, distance from ICK start 
in human or mouse. SspIa and EcoRVa sites, double arrows. Underlined, motifs identical in the mouse and human. Gap, omitted bases in alignment. 
Putative binding sites, inserted name of the factor.
 
 
 
human  AATATTGGGATCCACCCTTCGGATGCGTGTGTTTTTATTTGCACCCTAAGTCAGCTACCTATAAA
-1935 
mouse  CTATATTTCAGAACAGCCCTTCTCTATGGATGGTTTCATTTGTACACTA-CTAACTACCTATGAT
-2248 
 
human  AAATGCCTTACTGTTTAAAAGAGGCCAAAAATTTAAA
-1898 
mouse  GTAGGTATTCGACGGATGCCAATATGTCAGTAGTTTT
-2211 
 
 
human  TTTTTTGTTTTAAAGGAGACTCTAGGGCTTAAGTCTTTTTAAGGATAAATTTCCTCCCAA
-1838 
mouse  CTTTGTTTTTTAAAGGAGACTCTAGATTTCAGGTCTTTC-AAGAAAAACACTTCTCCCAA
-2152 
 
human  TGAACTCCTTAAAATTGAATTTTGAA--------ATTTAAA-----TTGGGGGGAAAGGT
-1791  
mouse  TGATCCCTTTAAAATTAGGTTTTAAATGGAAAAAATTTAAAAAAGACTAATAACAGACGT
-2092 
 
human  ----TAAAT--CTAAGATTTATAATAGAATAAAATGATAAATG-----------TGACT-
-1749 
mouse  GATTTGAATTCCCCAGATTGGGGCTTGGAGAGATGGCTCAGTGGTTAAGAGCACTGACTG
-2032-gap- 
 
human  --------------------CTTACATACTGAG--AATGAAGTATTGAAATAGTT--TGG
-1713 
mouse  GGGGGTCTGATGACCTCACACAGACATACTAAACCAACAGTGCACATAAAACAACAATGA
-1912 
 
human  GAACAAA---TCTGTTTC---ATTTAAAATGTTGAGTGCTAGTTTAAAATAGCCTGGTCAAT
-1657 
mouse  GCCCTAAACGTCAGTTTTCAGATGAAGAGTGAGGATTGAATGTTTAAGGCGGGCTGGCCAAT
-1850 
  
human  TACACAGATGGTTTCTTTTATTCTAGCAAGTA--------ATTAAAGCTTAATAAAATAA
-1605 
mouse  TA---ACACGTTTTCTCTTATCCAAACGAGTTGATGAAGTAGTAAAATTTAACAAGATAA
-1793 
 
         
human  -TATTTGTAAAGATAAATTGAGCA---------TTAAAATACTGTTATGCTTCATAGC
-1557-gap- 
mouse  ATATTTGTGAAGATAAATTCAGTACCTACCTAATTGAAACCCTGTT-TGCTTCACAGC
-1736-gap- 
 
human  TATCCACTAGACCTCATTACAAGGTTATATT--CTCATATTATATTTACAGGATTATAAT
-1467 
mouse  AAACCAATAGCCGTCATCACTGGTTTTTATTATCTCAACATGTATTTACTGGGTCATAAT
-1616 
 
human  TTCCTGAGG-CCAAAACTACTGATCTAGGCTACTTACTAGCCTAGCAGACTCTTGCTAAA
-1408 
mouse  TTCCCAAGGGCCAGGACTTCTAATATAAACTGCTTAGTAACCCAGTGGACCTCTGCC-AA
-1557 
 
human  AGGTAGACCAAGACAGTACCTTTGTTTGCCAGGTAGACCTGCTTGGACAATTTGACTAAAA
-1347 
mouse  AGGTAGACAAAGGCAGTTCCTCTCTTTGCAAGGCAGACTGGCTTGAACTGTTAAGTTTGA-
-1497 
 
human  CTGATCATTTTACTTTAGAAATTGCTTTTCATGGGAGTAGTATATGACTTGTTAGATTCC
-1287 
mouse  TCATTTTAGTTACTTTTAAAGCTCCCCTTTAT--GAGCACTATATGACTTATTAGGCTCC
-1431 
 
human  TTGTCGTGTCTCTATCTTTTCACTGATAATGATTTTCAGTTTTCATTTGCCATATGGGCT
-1227 
mouse  TTGTCTTGT--------GTTCACTAAGGAGGACTTGTGATTTCCATTTGTCCTATGGGCT
-1379 
 
  
human  GGCTGTTAAATAGGTAAACACAAAGGTAGATA---TCAATGTTATACATATGTCAAGTGG
-1170-gap- 
mouse  AGCTATCACATAGGTAAACAAGGAGACAGGTAAGGTTAACAGAAGCCCTGGGGAACTTGA
-1319-gap-
 
 
 
human  TATGATCA--GCTGGGAATTGTAAACTCAGAGAACAGTCCACAAAGTGTCAAAGGGTTAC
-930 
mouse  ATCAAGCATGGCTGGGAAGAGTTAAATTCAAAAAGAGTT----AAATTCAAAAGAGTTAC
-1023 
 
human  TGCTTTATTAATTAAATTTGTGTTGCTTACAGCAGTGTGAC--------CCAGCAACATT
-878 
mouse  TGATTTATTGGTCAAAATAGTGTTATTTAGAAAGATGTGGGTCTCCAGACCAGCAGCATC
-963 
   
 
human  AGCACCAGAAACTCTGAGAGTGCAGCCCAGGAGTTTGTTTTAACAAGTCCTCCAGGTGGT
-818 
mouse  TGCCCCAAGAACTTCTGGTGTGGGGCCTAGCAATTTGTTTTTACTAGCCTTTTGGGTTAC
-904 
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experiments. Western blot analyses were performed to
ensure that cells expressed the transcription factors (see
additional file 1). β-catenin also significantly enhanced
ICK-7 activity (Fig. 8). This helps explain the presence of
ICK mRNA in crypts and absence of message in the dif-
ferentiated cells of the epithelium [4], but more definitive
studies are necessary. Expression of a dominant-negative
form of TCF4 caused a small increase in basal activity in
these experiments, indicating that basal luciferase activity
of the minimal reporter is not driven by β-catenin in
HEK293T cells. This mutant lacks a binding site to part-
ner with β-catenin [24].
Given the importance of TCF7L2 (TCF4) for crypt biol-
ogy and colon cancer [24], we had looked for conserved
Figure 6 Alignment of the human and mouse ICK promoter sequence for the EcoRVb-PstIb fragment. Double arrows, EcoRVb and PstIb sites. 
Single arrow, start sites of indicated reference mRNAs. Putative binding sites, inserted name of the factor.
 
 
 
 
human  TCTGATGCTTCCCGCTAATGTTTAAGAACTGTTGGCTTAGAACAATTATGTAAATTTAAAAT
-756 
mouse  ------------------------------CACCCTGTGGAACGATAGAGT--------
-882 
 
human  CAGGGACCTGGAAGCAACTT--------CTTTATTCAAACCGCTCTAGCCTTATA----
-709 
mouse  CCAGAGCCGGGTGGTAATTTGTTTTTTTTTTTTTTCAAAATGCTTCAAAGCTATCCTTT
-823 
 
human  AGGATGATTTAAGGTAATGTCTACAATAT
-680 
mouse  AAGATGATTTAAGGTGGGTCCCACAATAG
-794 
 
human  CACTTATG-ACATAAAT-CAATGTGTTATAAAATTACGTGTTAGT--GTCAGATTCCCTA
-624 
mouse  TATATATGTATGTAGGTATGACTTATTTTAGAGAGGTTTGAGACTTGGTCTCATTACATA
-558 
  
                                             
human  TAACTAGTTACAGAGGACGATTGTTGTGTAGA---GGATATCT---GACTAGAGTCAGTT
-570 
mouse  GTCCTAGCTGTCCTTGA-ATTCACTATGTAGACCAGGCTGTCCCAGAACTCACATAGATT
-558 
 
human  TCC--CATCTGGGTTAAGAGTCCAGTCTTTACA----------ACTACTTG---CTAACA
-525 
mouse  CACTGCATCTGCCTCCTAAGTGCTGTGATTAAAGGTGTACACCACCACTCAGGCTTTACA
-498 
 
 
human  ACATAAAAACTCTTAAGAGTTCAAAGGAATG-CTAACAGGCAATCAGTTGCGTTTTCATT
-466 
mouse  ATATAATTTATGTTGTGAGTTTGTTCTAGTGGTTCTCTGCCTTCCTAATACAGTTCC---
- 
 
 
human  TTATTTTTCTGTAAAGGT-AACATGAAATTTGCTGTT-TAACCACTT--TGAATACAATT
-410 
mouse  TCATGTTGTGGTAATCACCAACTTTAAAATTATTTTTGTTGCTACTTCATAACTGTAATT
-498 
 
human  CAGTGGCATTGATTACTTTCACAATGTCGTGCCACCTCAACTACGTTTTTTCAAATCAGA
-350 
mouse  TTGCTACTGTTATGAATCATAATGTAAATATCTGTGTCTTCTG-ATGGTCTTAGGCCACC
-439 
 
 
human  AAAATGTTTTCACAACGATTATCTTTAATTTAATGTGCTCAG--AACGTCCATCGACAGC
-292 
mouse  TTTGAATCCCCAAAAGGGTTAACCACAGGTTGAGAACCTCTGCAAACAGTGTTAGATTTC
-379 
 
human  CT-CCATTTCTAAGTCTTGATGGTTG-ATCGAGCCGATCTGCAAC-----GAGGCGTTCG
-239 
mouse  CTACCACTGCATAGAAAGGAGTGTTGCATCTCCTTGGTTTCTCACTTCGGAAGCTATCCA
-319 
 
human  TTCGGAGTCGGAGA-TCGCCTTGCGGT---------------------------------
-213 
mouse  TTCAGTCTTTCAAACTTACGTTGCAATAATGCTGAAATCATTTTTTCTACTGTGGTTAAA-gap- 
 
human  CAGCGGGGGTTAGGGGTCCCTGGGCGCTGTGCTGCCC-TCGGCC---CAGAGCTGCGCCTG
-156 
mouse  -AGCGGGGGCTTCCCTTATTTGAGTATTTTGGGGTCAATCAGCCTGTCAGTGGCAAGTCTG
-109 
 
human  GCGGCTCGGCCGCGCGAGCCAGG-GCGAACAGG-------------------------
-124 
mouse  -CGGCTCCCCCGGGTGGGTTCGCCGCAGCCCAGaagctcaacgctgccctctgccgagca
-50 
 
                                               PstI
b 
huma   ACGCAGTGCAGGGACGCGCAGGGCCAGCGAGGGGAGCTGCAGGGTAACTTTTCCCAGGGA
-64 
mouse  CGGTGGTGCAGGGCCGCGCGGGGCCAGCGAGGGGAGCTGCAGGGCAGCTTTTC-CAGGGA
+21 
                                            NM_019987(mouse) 
                                     
 
human  AAGCGGCCGGTCGTCCCCAGTAGAAGCCACCCAGCCTTTTGTTTGTTTTCCTGCCGGAGG
-4 
mouse  AAGCGGCTGGTCGTCCCCACTAGAAGCCACTCTGCCTTTTGTTTGTTTTGCTGCCGGAGG
+84  
 
           NM_014920.3 (human)  
human  CTGGAAAACGGCCGGGTTCCTGCTGCACTACCATGCGCCGTGCGGCCCGTGCGACTCGCC
+56 
mouse  CCGCGGAGCGGC-GGGTTCCTGCTGGA-TGCCACGCGCTGACGGGTGTGGACTTGCCGGG
+142 
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TCF4 sites and failed to identify them because no
TCAAG motifs were aligned by EMBOSS between
human and mouse. Recently, a genome wide study for
binding sites defined the majority of the in vivo-occupied
TCF7L2-binding sites in LS174T colon cancer cells as
evolutionarily conserved A-C/G-A/T-T-C-A-A-A-G
motifs [25]. The motif 5'-AGTTCAAAG-3' at -539 nt
(Fig. 6) is a perfect match for TCF7L2 in the human ICK
promoter. The motif, 5'-CACTTTGAAT-3', at -456 nt is
also a perfect match. There are also close matches for
TCF7L2 motifs in the mouse ICK promoter in the same
regions. These are 5'-TGCTTCAAAG-3' at -1471 nt (in a
gap and not shown in Fig. 5.) and 5'-CTTTGAATC-3'
(Fig. 6).
CDX1 or CDX2 plasmids increased activity insignifi-
cantly under the conditions of our experiments. CDX1
and CDX2 are distinct genes encoding related homeobox
transcription factors known to have overlapping, but also
distinct functions. Both CDX1 and CDX2 are expressed
in crypts. Differential display identified MOK as a gene
u p r e g u l a t e d  b y  CD X 2  i n  s t a b l y  e n gi n ee r ed  I E C - 6  c e l l s
with integrated Tet/Off™ [26]. CDX1 was a much weaker
activator of MOK reporter. CDX2 strongly activated a
luciferase construct for the MOK promoter, and CDX2
bound to the 5' untranslated region of MOK in cells.
These data prove that CDX2 regulates expression of a
protein kinase related to ICK in vivo.
ICK was also characterized in sufficient detail to sug-
gest, but not prove, that switching on CDX2 expression in
also induced ICK mRNA in IEC-6 cells. This requires
restudy. There are four TTTA(C/T) motifs (at -544, -522,
-466, and -455) in the minimal promoter for human ICK
for CDX2. Three TTTA(C/T) motifs for CDX2 are in the
same region (at -275, -341, and -366 nt). A longer binding
Figure 7 A minimal promoter for ICK in HEK293TT and HCT-15 cells. Data for ICK were normalized to ICK-9 construct lacking the ICK start site.
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Figure 8 Expression of FOXA 1, FOXA2, and β-catenin significant-
ly increase ICK reporter activity. HEK-293T cells in 12-well plates 
were transiently co-transfected with the ICK-7 luciferase reporter, the 
control CMV-β-galactosidase reporter, and with expression vectors en-
coding the various transcription factors or vector control (VC) essential-
ly as described for NFκB reporter assays [64]. The β-galactosidase 
activities were used to normalize the luciferase values. Co-transfec-
tions were also performed with the promoterless ICK-9 luciferase re-
porter, which served as a negative transcription control. Western blot 
analyses were performed to ensure that cells expressed the transcrip-
tion factors (see additional file 1). No suitable antibody was available 
for CDX1. Data represents the mean + SD of two independent experi-
ments performed in triplicate.
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consensus was determined for chicken CDXA (CDX1) as
5'-AWTWAR-3', where W is (A/T) and D is (A/G). Motif
5'-CATAAAA-3' at -523 nt, overlaps a consensus for
CDX2, and closely matches the CDX1 consensus, and is
near a site for TCF7L2 (TCF4). CDX1 can interact with
LEF1 on promoters [27]. An exact match for CDX1, 5'-
AATAATG-3' is present at -294 nt in mouse but is not
adjacent to a consensus mouse TCFL2 site. The roles of
CDX1 or CDX2 if any on ICK expression in vivo are yet to
be defined.
A known caveat with co-expression experiments is that
activation may arise at motifs that are not motif used in
the endogenous promoter. Thus, our conclusion that ICK
promoter is regulated by a FOX-family protein, β-catenin,
and CDX remains an hypothesis, albeit a stronger one
given our data, until gel shift and site mutations in vitro
and ChIP and knock-down experiments in vivo can be
performed.
ICK mRNA is increased in human cancer
Serial analysis of gene expression (SAGE) is a quantitative
method to estimate copy number of a specific mRNA
[28]. The SAGE method depends on identification of
sequence tag(s) with high specificity for a gene. Tags from
many mRNAs are isolated from polyA+ mRNA, linked
together, and the linked tags are sequenced. Tags appear-
ing in the sequence are counted. The ICK 10-base tag
(TCAACCTTAT) maps to the ICK gene locus and to no
other locus, and is found near the 3' end of the mRNAs
encoding ICK, such as isolated cDNA BC152464.1 and
the reference mRNAs NM_014920.3, and NM_016513.4.
ICK mRNA is >6 kb and has a 3.5 kb 3'UTR, making ICK
mRNA among the top 5% in length in the human
genome.
Several high quality SAGE data sets for normal breast
tissue and breast cancer were available to us (Table 1). We
searched each of these data sets for the ICK specific tag.
The ICK transcripts are very non-abundant in breast tis-
sue and are greatly increased in some breast cancers. No
comparable studies are available with a newer 17-base
SAGE tag. Microarray data for the NCI60 cancer cell
lines show ICK is higher in the breast, colon, and lung
cancer derived lines http://biogps.gnf.org.
Segments important for FBX9 promoter activity
The 4.5 kb XhoI-XhoI segment (Fig. 1) contains start sites
for two (viz. NM_016513, NM_014920) of the three refer-
ence FBX9 mRNAs. (The start site for the third
(NM_012347) is ~5.5 kb distant.) Construct FBX9-2,
missing the PstIa-ApaIb fragment, was slightly more active
or unchanged in comparison to FBX9-1 in four of five
lines, and serves as the reference for comparison with the
two 5' end deletions we were able to obtain.
HCT-15 has the highest relative FBX9 promoter activ-
ity of all six lines. Removal of the ICK half of the pro-
moter caused a large and significant decrease (>75%) in
FBX9 activity in breast (AU565, SKBR3), colon (HCT-15,
KM12) as well as in HEK293T cells. Compare construct
FBX9-3 to FBX9-2. Although FBX9 activities were lower
than ICK activities, FBX9 activities greatly exceeded
background. Since the ICK half removed contains posi-
tive cis-acting elements for ICK as well, this result is con-
sistent with co-regulation of FBX9 and ICK. Interestingly,
extending the end deletion by removal of SmaIb-HindIIIa
reverses part of this loss in all the lines except AGS, sug-
gesting repressing elements for FBX9 exist in HindIIIa-
XhoI. A repressor is one hypothesis for the differential
regulation of FBX9 versus ICK in the cancer cell lines.
Another is that the products (ICK and FBX9) feedback at
the promoter to regulate each others expression, depen-
dent upon the kinase activity of ICK and/or the ubiquitin
ligase activity of a hypothesized SCF complex containing
FBX9.
Discussion
The full intergenic segment (constructs ICK-1 and FBX9-
1, respectively) was active in both orientations in all six of
the lines, suggesting that ICK and FBX9 share a bidirec-
tional promoter. Analyses in the different lines show ele-
ments in the common SspIb  to PstIb  fragment are
important for bidirectional activity, and may account for
the correlated expression of FBX9 and ICK in microarray
data that motivated this study. Our analyses show that the
intergenic segment is not a constitutive, bidirectional
promoter because the FBX9 activity relative to ICK is
variable. This report extends our knowledge of ICK regu-
lation: (i) ICK shares a bi-directional promoter with an
uncharacterized F-box protein, (ii) the putative ICK 5'
start is in a GC-rich region containing a CpG island that
is active as a promoter, (iii) a minimal promoter can be
regulated by expression of FOXA and β-catenin.
ICK is conserved and almost all metazoans and some
unicellular species (including S. pombe) have homologs of
both MAK and ICK. Human ICK/MRK and human MAK
are nearly identical in the kinase domain. Danio rerio has
one gene that encodes a protein more similar to ICK than
MAK. This genome is an anomaly, as other teleost fishes
have both ICK and MAK genes. ICK message is highly
expressed in developing retina in zebra fish (ZDB-GENE-
030131-7279). Interestingly, ICK or MAK expression is
greatly increased in retinal cancer compared to normal
retina (SAGE/cDNA Virtual Northern) according to data
at the Cancer Genome Anatomy Project).
Our prior work established ICK as the prototype for a
group of CDK and MAPK like protein kinases regulated
by phosphorylation in a TDY motif [1,29]. No canonical
MAP kinase cascades have yet emerged for activation ofSturgill et al. Molecular Cancer 2010, 9:104
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ICK, in its limited study. An alternative mechanism is
transcriptional regulation followed by activation by active
protein kinases. The ICK homolog in S. cerevisiae is regu-
lated by transcription, and is subsequently phosphory-
lated in the TXY motifs dependent upon yeast CAK [29].
In an insightful commentary, Adachi and Lieber [30]
noted that of twenty, functional bidirectional promoters
reported in the literature at the time, several directed
transcription of genes implicated in DNA repair: includ-
ing BRCA1/NBR2, DNA-PKcs/MCM4, ATM/NPAT,
DHFR/MSH3, and Ku86/TERP. While not unique to this
class, they concluded placement of genes into bidirec-
tional promoters is a common scenario for DNA repair
genes. Clearly, this correlation does not imply anything
about function of FBX9 or ICK. Nevertheless, this is of
interest since ICK has interactors that may have some
role in DNA repair [29].
FBX9 is predicted to encode an F-box protein [31]. F-
box proteins contain a conserved domain that interacts
directly with Skp1 as one of the components of a SCF
(Skip, Cullin, F-box) ubiquitin ligase. The F-box protein
provides a specific interaction that specifically recruits a
substrate, possibly in a specific form (phosphorylated or
un-phosphorylated) for degradation by linkage to ubiq-
uitin. The substrate specificity of FBX9 is unknown.
FBX9 could produce three forms (403-447 residues)
based on predicted transcripts. FBX9 has a possible
homolog in S. cerevisiae named Hrt3p (E = 2.9e-14 over
334 residues), discovered in a single genome search of S.
cerevisiae  using SSEARCH http://fasta.bioch.vir-
ginia.edu. Reciprocally, a search of NCBI human refer-
ence proteins with Hrt3p using SSEARCH finds FBX9 as
the very first hit. Hrt3p is a putative nuclear ubiquitin
ligase component based on large-scale studies (see Sac-
charomyces Genome Database (Stanford University,
Leland, CA). Hrt3p interacts with Cdc53p and Skp1p by
affinity capture mass spectrometry [32], and shows dos-
age lethality with cdc34.
The intestinal epithelium has advantages for studies of
differentiation, one being the segregation of the epithe-
Table 1: ICK-specific tag TCAACCTTAT in SAGE Data sets for Breast Tissuesa
Data Setb Descriptionc Number, TCAACCTTAT
SAGE Tagsd
Data Set TCAACCTTAT,
TAGS/Millione
Data Set, Total Tags
in SAGE Libraryf
GSM383793 Mammary gland, DCIS-4, High Grade, 
Comedo
10 165 60605
GSM383790 Mammary gland, IDC, Node+, Gr3, ER+, 
PR+
8 119 67070
GSM383827 Metastasis to Node, from Primary Gr3, 
ER-, PR-
5 111 45087
GSM383796 Mammary gland, IDC-4 High Gr, Node-, 
ER-, erbB2-, p53+
7 109 64095
GSM383794 Mammary gland, DCIS, High Grade, 
Comedo
4 93 43098
GSM383795 Mammary gland, IDC-3, Low Gr, Node-, 
ER+, erbB2-, p53-
5 73 68891
GSM383797 Breast CA, IDC-5, Low Grade, ER+, 
erbB2-, p53-
4 66 60451
GSM383789 Mammary gland, IDC, Node+, Gr3 ER-, 
PR-,
1 25 39364
GSM383828 Metastasis to Node, from Primary Gr3, 
ER+, PR+
1 17 60343
GSM383824 Metastasis to Lung, Primary Gr3, ER+, 
PR-low, Her2-
0 N/A 49794
GSM383829 Mammary gland, Gestational 
Hyperplasia
1 16 61704
a SAGE data sets for libraries from tissue.
b Data set names provided by NCBI.
c Notes from clinical annotation for source and pathology.
d Absolute tag count for TCAACCTTAT in the data set.
e TAGs per million non-linker tags.
f Total tags.Sturgill et al. Molecular Cancer 2010, 9:104
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lium into defined zones containing stem cells, zones for
proliferating transit cells, and a zone of non-proliferating
differentiated enterocytes [33]. Other differentiated prog-
eny, enteroendocrine cells, goblet cells and Paneth cells,
derive from the same stem cells and assume characteristic
positions in the epithelium. The epithelium is also con-
stantly turned over during adult life. Since transcription
factors regulate differentiation and are relatively easy to
study, a large fund of knowledge existed for transcription
factors in the gut that could suggest functions for ICK.
This was a major motivation for our study. We found that
FOXA1 and FOXA2, β-catenin activate an ICK reporter.
These factors are known to regulate proliferation and dif-
ferentiation in the intestinal epithelium [24,34,35].
Recently, mutation of ICK was linked to neonatal
deaths in humans. A study of a cohort of malformed new-
borns in Old Order Amish families revealed R272Q
mutation of ICK as the probable cause of a severe reces-
sive, endocrine/cerebro/osteodysplasia (ECO) syndrome
[36]. R272Q mutation causes loss of nuclear localization
and kinase activity of ICK [1,36]. Abnormalities occurred
in multiple systems, including bone, brain, and endocrine
tissues [36].
If the R272Q mutation in ICK can be confirmed as
causally related to the ECO syndrome, ICK is unequivo-
cally required for normal development. The finding war-
rants testing a similar knock-in mutation in mouse. MAK
has been knocked out in mice with no phenotype noted
except for reduced fertility and reduced sperm motility
[37]. Lack of a clear phenotype for a MAK knockout may
be due to presence of ICK. However, the mild motility
phenotype mentioned for sperm may be significant.
A single ICK/MAK homolog (LmxMPK9) in Leishma-
nia mexicana regulates morphogenesis of the flagella
[38]. Loss of LmxMP9 causes elongated flagella whereas
overexpression of LmxMPK9 causes shortened or no fla-
gella [38]. Genetic studies of flagella morphogenesis in
Chlamydomonas reinhardtii identified a CCRK homolog
as well as a homolog of MOK [39] as having function in
flagellar morphogenesis.
These links to flagella phenotypes seem abstruse for
human disease except for the fact that there is a major
developmental pathway in cells that respond to Sonic
hedgehog that depends on primary cilia [7]. CCRK inter-
acts with Broadminded (Bromi) in the Sonic hedgehog
pathway. We believe the cluster of genes ICK, MAK, and
MOK may be regulated by CCRK and play a role in Sonic
hedgehog signaling that was preceded in evolution by
roles in flagellar morphogenesis in unicellular eukaryotes.
Another possible function for ICK is cell cycle regula-
tion. The related kinase in budding yeast Ime2p (inducer
of meiosis 2) controls a checkpoint that times meiotic S-
phase and controls meiotic progression [40,41]. ICK can
affect the cell cycle since reducing its expression in
Colo205 cells causes arrest in G1 [3].
The interactors suggest leads for ICK function to the
degree that the functions of the interactors are under-
stood [29]. One interactor is multifunctional PP5, a pro-
tein phosphatase that recognizes substrates by a docking
domain. The best established roles of PP5 are in control
of apoptosis by inhibition of ASK1 [42]; in the cell cycle
by suppressing a pathway regulating the expression of
p21(waf1) [43]; in DNA repair by dephosphorylation of
substrate DNA-PK [44]; and in ATR-mediated check-
point activation via an unknown substrate [45].
The second ICK interactor we identified is the protein
in literature BAT3 (NCBI designation) or Scythe or
BAG6, whose functional roles are becoming clearer even
if its names are not. All three names are common. ICK
phosphorylates BAT3/Scythe at T1080 in vitro and in situ
[29]. BAT3 functions demands more study. The name
Scythe came from ability of the protein to bind reaper in
in vitro capture experiments [46], leading to several
reports supporting the idea that BAT3 functions in apop-
tosis [47]. BAT3, for example, can interact with an inter-
membrane mitochondrial protein apoptosis-inducing
factor, which seemed to fit the apoptosis-function
h y p o t h e s i s  [ 4 7 ] .  A  D e l e t i o n  o f  B A T 3  ( - ,  - )  d o e s  c a u s e
lethality and major abnormalities in development, and
not surprisingly increased apoptosis in tissues. This is
also consistent, but increased apoptosis may result indi-
rectly, not because of a proposed model that BAT3 is a
direct apoptotic regulator. BAT3 (-, -) fibroblasts are not
very different from wild type fibroblasts in propensity to
a p o p t o s e  e x c e p t  t o  a  v e r y  f e w  s t i m u l i .  B A T 3  i s  n o t
directly functioning in any known apoptosis cascades. A
second literature supports function of BAT3 as a co-
chaperone with Hsp70 and regulation of protein stability
and ubiquitin-dependent degradation [48]. The kinases
ICK, MAK, and MOK bind a chaperone Cdc37/p50, a
nonexclusive partner of Hsp90 [49].
Finding many interactions for BAT3 suggests a scaf-
folding domain. We believe a unifying hypothesis for the
defects in development in the BAT3 (-, -) mouse may
c o m e  i n  t h e  f u t u r e  f r o m  v i g o r o u s  s t u d y  o f  i t s  n u c l e a r
functions. BAT3 contains a nuclear localization sequence
[50]. Recent work establishes that nuclear retention of
BAT3 can be dependent upon cellular transformation
[51]. In the nucleus, BA T3 and SET1A form a complex
with Boris to modulate H3K4 histone dimethylation
marks and gene expression [52]. The latter discovery fits
nicely with nuclear localization of BAT3 and transforma-
tion, abnormalities in development, and the high expres-
sion of BAT3 and MAK that occurs during
spermatogenesis [53,54]. H3K and H3K4 methylation
interplay to regulate gene activation [55]. Nuclear func-
tion of BAT3 is also indicated by its requirement for p53Sturgill et al. Molecular Cancer 2010, 9:104
http://www.molecular-cancer.com/content/9/1/104
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acetylation in response to DNA damage [56]. Certain
BAT3 genetic variations are strongly linked to suscepti-
bility to lung cancer [57].
Conclusion
ICK is transcribed from a GC-rich promoter that con-
tains a CpG island, and shares a bidirectional promoter
with FBX9. A minimal ICK promoter is activated by tran-
scription factors (FOXA and β-catenin) that regulate pro-
liferation and differentiation in the intestinal epithelium,
motivating additional studies in vivo. Several of the can-
didate motifs for FOX-family proteins are conserved
between mouse and human.
Methods
Cell lines
All of the cell lines were obtained from the American
Type Culture Collection (ATCC) in Manassas, VA except
the AGS cells (gift of Dr. Anil Rustgi, University of Penn-
sylvania). Cells were maintained in flasks (37°C) in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 5% fetal calf serum in an atmosphere containing 5%
CO2. For experiments, cells were seeded into 96-well
plates and allowed to attach and recover prior to transfec-
tion.
Plasmids and cloning
BAC clone RP3-341E18 was obtained from the Sanger
Gene Institute (UK). The 4.5 kbp XhoI fragment of RP3-
341E18 containing the ICK and FBX9 promoter region
was subcloned into the XhoI site in pBSII KS. A portion
of XhoI-XhoI in pBSII KS plasmid was cloned into the
promoter-less pGL3 fire fly reporter plasmid (Promega)
to generate constructs shown (Fig. 1), and all of the con-
structs obtained were verified by sequencing or diagnos-
tic restriction digests. Robert Costa (deceased, see tribute
and commentary on his contributions to the field [58])
sent plasmids (FOXA1, FOXA2, and FOXM) [59]. Juan
Iovanna (INSERM, Marseille, France) provided plasmids
for human CDX1 and CDX2 [60]. Marc van de Wetering
(Hubrecht Institute, Utrecht, Netherlands) gave us plas-
mids to express β-catenin and dominant-negative TCF4.
W e used MacV ector software for analyses of DNA. W e
used Qiagen™ kits to purify DNA for transfection, and
determined DNA concentration by optical density.
Western blotting
Anti-FOXA1/HNF3α and anti-FOXA2/HNF3β were rab-
bit polyclonal antibodies [61]. Anti-FOXM1 was from
Cell Signaling Technology. Anti-hemagglutinin antigen
(HA) peptide antibody used for detection of HA-tagged
β-catenin and HA-tagged dominant-negative TCF4 was
obtained from Santa Cruz Biotechnology. Anti-CDX2
was a generous gift from Nathalie Rivard [62]. Anti-tubu-
lin (Sigma Aldrich) was used as a control. No suitable
antibody was available for untagged CDX1.
Alignment of promoters and transcription factor 
bioinformatics
EMBOSS in setting 'needle' was used to align the human
and mouse FBX9-ICK intergenic regions promoters
http://www.ebi.ac.uk. We used literature and three online
sites for analysis of transcription factor motifs free to aca-
demicians: Consite [63] from the Karolinska Institute,
TESS [63] from the University of Pennsylvania, and Patch
for TransFac™ 6 at http://www.gene-regulation.com.
Assays
For 96-well assays, equal numbers of cells (1-2 × 104)
were seeded into wells and allowed to recover in 200
microliters of medium per well. Each luciferase construct
(200 ng DNA/well), along with 10 ng DNA/well of control
SV40-Renila luciferase plasmid (phRL-SV40 (Promega),
was transfected into cells (after seeding and recovery in
200 microliters of medium per well) using TransIt™-LT1
reagent (Mirus Corp.). Two days after transfection, both
luciferase activities were detected with Dual-Glo
luciferase assay reagent (Promega), and measured by a
Veritas™ micro luminometer (Turner) that has a dynamic
range of greater than nine decades. The values of fire fly
luciferase activity were normalized by control Renilla
luciferase activity for each well. Each measurement was
shown as means +/- SD of triplicate cultures and trans-
fections. Relative Light Unit (RLU) is defined as firefly
luciferase activity divided by renilla luciferase activity
t i m e s  t e n .  D a t a  i n  R L U  w e r e  n o r m a l i z e d  t o  c o n s t r u c t
ICK-1 (100%) for most comparisons; exceptions are
described in the figure legends. Data are representative of
multiple experiments.
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